Skip to main content

Table 2 Overview of NPSLE-manifestations in 72 SLE patients when applying three NPSLE attribution models 

From: Serum S100A8/A9 concentrations are associated with neuropsychiatric involvement in systemic lupus erythematosus: a cross-sectional study

 NPSLE-manifestation

SLICC A model

SLICC B model

ACR model

Any NPSLE-manifestation, n (%)

16 (22%)

23 (32%)

44 (61%)

Cognitive dysfunction, n (%)

0 (0%)

5 (7%)

26 (36%)

Headache, n (%)

N/A

N/A

22 (31%)

Depression, n (%)

0 (0%)

1 (1%)

13 (18%)

Anxiety disorder, n (%)

N/A

N/A

12 (17%)

Autonomic neuropathy, n (%)

7 (10%)

8 (11%)

10 (14%)

Cranial neuropathy, n (%)

7 (10%)

7 (10%)

7 (10%)

Cerebrovascular disease, n (%)

1 (1%)

5 (7%)

5 (7%)

Demyelinating disease, n (%)

3 (4%)

3 (4%)

3 (4%)

Myelitis, n (%)

2 (3%)

3 (4%)

3 (4%)

Confusion, n (%)

1 (1%)

2 (3%)

3 (4%)

Polyneuropathy, n (%)

1 (1%)

1 (1%)

3 (4%)

Seizures, n (%)

1 (1%)

2 (3%)

2 (3%)

Mononeuritis, n (%)

1 (1%)

2 (3%)

2 (3%)

Aseptic meningitis, n (%)

1 (1%)

1 (1%)

1 (1%)

Psychosis, n (%)

1 (1%)

1 (1%)

1 (1%)

Chorea, n (%)

0 (0%)

1 (1%)

1 (1%)

Guillain-Barré syndrome, n (%)

0 (0%)

0 (0%)

0 (0%)

Plexopathy, n (%)

0 (0%)

0 (0%)

0 (0%)

Myasthenia gravis, n (%)

0 (0%)

0 (0%)

0 (0%)

  1. One patient may have more than one NPSLE-manifestation. NPSLE: Neuropsychiatric Systemic Lupus Erythematosus. SLICC: Systemic Lupus Erythematosus International Collaborating Clinics. ACR: American College of Rheumatology. N/A: Not applicable